Unoprostone ophthalmic Pregnancy and Breastfeeding Warnings
Unoprostone ophthalmic is also known as: Rescula
Unoprostone ophthalmic Pregnancy Warnings
Animal studies have shown an increase in the incidence of miscarriages, an increase in the incidence of premature delivery, a decrease in live birth index, and a decrease in weight at birth. There are no adequate and well-controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Unoprostone ophthalmic Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
References for pregnancy information
- "Product Information. Rescula (unoprostone ophthalmic)" Ciba Vision Ophthalmics, Duluth, GA.
References for breastfeeding information
- "Product Information. Rescula (unoprostone ophthalmic)" Ciba Vision Ophthalmics, Duluth, GA.
See Also...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
